Form 4: Incyte Executive Michael James Morrissey Reports Stock Award

Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corp, reports the acquisition of 10,552 shares of common stock through a restricted stock unit (RSU) award on January 31, 2025.

Summary

• On January 31, 2025, Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corp, acquired 10,552 shares of common stock.
• This acquisition was through a grant of restricted stock units (RSUs).
• The RSUs vest 25% annually over four years, contingent upon continued service with Incyte.
• The RSUs are settled for shares of common stock on a one-for-one basis.
• Following the reported transaction, Morrissey beneficially owns 81,515 shares of common stock, including 27,507 shares issuable pursuant to previously reported unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an executive stock award, which is neither particularly positive nor negative.

Positives

• The RSU award aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives, buy or sell their company's stock. This filing indicates an award of stock to an executive, which is a common practice in executive compensation packages within the pharmaceutical industry.

Comparison to Industry Standards

• Stock awards are a common component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock awards and options to incentivize their executives.
• The vesting schedule of 25% annually over four years is a typical vesting arrangement for RSUs in the industry.

Stakeholder Impact

• The RSU award could have a slightly positive impact on shareholder sentiment as it aligns executive interests with company performance.
• Employees may view the award positively as it reflects the company's investment in its leadership.

Key Dates